HT Partners LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 5.7% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 14,481 shares of the company’s stock after selling 879 shares during the period. Johnson & Johnson comprises about 0.8% of HT Partners LLC’s portfolio, making the stock its 10th largest holding. HT Partners LLC’s holdings in Johnson & Johnson were worth $2,112,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Aries Wealth Management raised its stake in Johnson & Johnson by 0.3% in the fourth quarter. Aries Wealth Management now owns 27,932 shares of the company’s stock worth $4,025,000 after buying an additional 75 shares in the last quarter. Portland Global Advisors LLC raised its stake in Johnson & Johnson by 0.9% in the third quarter. Portland Global Advisors LLC now owns 8,744 shares of the company’s stock worth $1,131,000 after buying an additional 78 shares in the last quarter. SRS Capital Advisors Inc. raised its stake in Johnson & Johnson by 0.5% in the third quarter. SRS Capital Advisors Inc. now owns 17,452 shares of the company’s stock worth $2,258,000 after buying an additional 79 shares in the last quarter. Alta Capital Management LLC raised its stake in Johnson & Johnson by 3.9% in the third quarter. Alta Capital Management LLC now owns 2,184 shares of the company’s stock worth $282,000 after buying an additional 82 shares in the last quarter. Finally, G&S Capital LLC raised its stake in Johnson & Johnson by 1.8% in the third quarter. G&S Capital LLC now owns 4,668 shares of the company’s stock worth $604,000 after buying an additional 84 shares in the last quarter. Institutional investors and hedge funds own 67.28% of the company’s stock.
A number of equities analysts recently issued reports on JNJ shares. Wells Fargo & Co increased their price target on shares of Johnson & Johnson from $155.00 to $165.00 and gave the stock an “overweight” rating in a research note on Thursday, January 9th. Sanford C. Bernstein raised shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price target for the company in a research note on Friday, October 11th. Cantor Fitzgerald started coverage on shares of Johnson & Johnson in a research note on Wednesday, November 27th. They issued an “overweight” rating and a $160.00 price target for the company. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $158.00 price target for the company in a research note on Wednesday, December 18th. Finally, Credit Suisse Group reissued a “buy” rating and issued a $163.00 price target on shares of Johnson & Johnson in a research note on Tuesday, December 31st. Three analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $159.33.
Shares of JNJ opened at $147.01 on Thursday. The stock has a market cap of $385.62 billion, a PE ratio of 17.97, a price-to-earnings-growth ratio of 2.36 and a beta of 0.71. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.00 and a current ratio of 1.26. Johnson & Johnson has a fifty-two week low of $125.00 and a fifty-two week high of $147.84. The firm’s 50-day simple moving average is $143.07 and its two-hundred day simple moving average is $134.77.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 15th. The company reported $2.12 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.00 by $0.12. The business had revenue of $20.73 billion for the quarter, compared to analysts’ expectations of $20.14 billion. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.81%. The business’s revenue was up 1.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.05 earnings per share. Equities research analysts predict that Johnson & Johnson will post 8.66 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 25th will be issued a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a yield of 2.58%. The ex-dividend date is Monday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.45%.
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 2,017 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $141.07, for a total value of $284,538.19. Following the sale, the executive vice president now owns 51,736 shares in the company, valued at $7,298,397.52. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Hubert Joly acquired 5,000 shares of the business’s stock in a transaction on Friday, December 13th. The stock was acquired at an average price of $141.28 per share, for a total transaction of $706,400.00. Following the acquisition, the director now owns 5,000 shares of the company’s stock, valued at approximately $706,400. The disclosure for this purchase can be found here. 0.23% of the stock is currently owned by corporate insiders.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: What is Liquidity?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.